MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
37.797
+0.587 (+1.58%)
As of 12:22PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close37.210
Open37.190
Bid37.860 x 900
Ask37.870 x 1400
Day's Range37.100 - 37.860
52 Week Range30.690 - 47.820
Volume1,632,660
Avg. Volume3,970,557
Market Cap19.487B
Beta1.37
PE Ratio (TTM)43.60
EPS (TTM)0.867
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est46.84
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at the European Respiratory Society International Congress

    DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that positive new data from the companies' Phase 3 clinical program for YUPELRI™ (revefenacin) inhalation solution were featured in an oral presentation at the European Respiratory Society (ERS) International Congress 2018, which is being held in Paris, France on September 15-19, 2018. Presented data showed reductions in the rates of chronic obstructive pulmonary disease (COPD) exacerbations ranging from 15% to 18% in moderate to very severe COPD patients administered once-daily YUPELRI for up to 52 weeks as compared to placebo and tiotropium (Spiriva® HandiHaler®). While the YUPELRI Phase 3 program was not designed or powered to achieve statistical significance on differences in COPD exacerbation rates, researchers were interested in a post-hoc analysis of data from the studies to identify trends in this area.

  • Benzinga2 days ago

    The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

    Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...

  • See what the IHS Markit Score report has to say about Mylan NV.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Mylan NV.

    Mylan NV NASDAQ/NGS:MYL

  • Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija
    Zacks4 days ago

    Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija

    The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.

  • JNJ Stock Up 7% in the Past Month: What Drove the Bulls?
    Market Realist5 days ago

    JNJ Stock Up 7% in the Past Month: What Drove the Bulls?

    On September 12, Johnson & Johnson (JNJ) stock closed at $139.36. That was a 0.61% rise from the previous day’s closing price of $138.51. Currently, JNJ stock is trading above its 50-day moving average of $133.29 and below its 200-day moving average of $127.99.

  • Mylan Adds to Cardiovascular Portfolio With Launch of First Generic of Brevibloc® Injection in Single-Dose Bags
    PR Newswire5 days ago

    Mylan Adds to Cardiovascular Portfolio With Launch of First Generic of Brevibloc® Injection in Single-Dose Bags

    - Esmolol Hydrochloride in Sodium Chloride Injection is used to control heart rate - HERTFORDSHIRE, England and PITTSBURGH , Sept. 13, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: ...

  • Johnson & Johnson: Analyst Recommendations and Target Price
    Market Realist5 days ago

    Johnson & Johnson: Analyst Recommendations and Target Price

    Johnson & Johnson (JNJ) is one of the major healthcare companies in the world. It operates through its pharmaceuticals, medical devices, and consumer business segments. Although its pharmaceutical business generates most of its sales, medical devices and consumer business include a number of leading brands in their respective market spaces.

  • PR Newswire7 days ago

    Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018

    DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that new data from the Phase 3 YUPELRI™ (revefenacin) inhalation solution clinical program will be featured in an oral presentation at the European Respiratory Society (ERS) International Congress 2018, being held in Paris, France on September 15-19, 2018. The presented data will highlight chronic obstructive pulmonary disease (COPD) exacerbation rates observed in the Phase 3 clinical program of YUPELRI in patients with moderate to very severe COPD.

  • Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down
    Zacks7 days ago

    Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down

    Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra

  • New Strong Sell Stocks for September 10th
    Zacks8 days ago

    New Strong Sell Stocks for September 10th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • Why Is Mylan (MYL) Up 6.3% Since Last Earnings Report?
    Zacks11 days ago

    Why Is Mylan (MYL) Up 6.3% Since Last Earnings Report?

    Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Investor's Business Daily12 days ago

    These Hospital Systems Are Aiming To Undercut Biotechs, Drugmakers

    Generic-drug and biotech stocks plunged into the red Thursday after several leading hospital groups launched a nonprofit to undercut drug prices.

  • Reuters12 days ago

    Walgreens to supply Kaleo's allergy shots as EpiPen shortage drags

    U.S. drugstore chain Walgreens Boots Alliance Inc said on Thursday emergency allergy shots from Kaleo will be available in its stores, the latest effort to address shortages of the lifesaving treatment during the back-to-school season. There has been an acute shortage of Mylan's EpiPen, which dominates the allergy market, with the health regulator last month extending the expiration date of specific lots of the treatment. In August, Mylan issued a warning that the devices may not always be available.

  • Mylan Suffers Several Setbacks: What's in Store in 2H18?
    Zacks14 days ago

    Mylan Suffers Several Setbacks: What's in Store in 2H18?

    Mounting competition and recent setbacks cast a pall over Mylan's (MYL) near-term performance.

  • ETF Trends18 days ago

    Biotech Fund Flows, Including ETF Activity, Remain a Driver to Watch

    The biotech sector performed well in August, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) up almost 3.5% this week alone. Research by Raymond James indicates that in just the past week, biotech ...

  • The Wall Street Journal23 days ago

    EpiPen Shortage Hits Back-to-School Season

    Parents are scrambling to find pharmacies carrying EpiPens for the new school year as regulators and the drug’s manufacturer struggle to abate a continuing global shortage of the lifesaving devices. EpiPens, the emergency epinephrine treatment for allergic reactions, have been in short supply since at least May, when the U.S. Food and Drug Administration first declared a shortage. A rival epinephrine injector product, a generic version of Adrenaclick made by Amneal Pharmaceuticals Inc., is also in short supply, according to the FDA.

  • There’s an EpiPen shortage—and parents fear for their allergic children headed back to school
    MarketWatch24 days ago

    There’s an EpiPen shortage—and parents fear for their allergic children headed back to school

    Only after calling between eight and 10 pharmacies in her New Jersey area was Wachtler able to find a two-pack of the generic EpiPen—and it was the pharmacy’s last box. Mylan’s (MYL) brand-name EpiPen and the authorized generic, two widely used allergic reaction treatments, as well as Amneal Pharmaceuticals’ (AMRX) generic auto-injector Adrenaclick were added to the Food and Drug Administration’s drug shortage list in May.

  • MarketWatch25 days ago

    Popular health-care ETF finishes at an all-time high as stock market rallies

    A popular exchange-traded fund that tracks the health-care sector finished at its highest level in its history on Friday. The Health Care Select Sector SPDR ETF (XLV) advanced by 0.4% to reach 91.82, representing its highest level since the vehicle was created in 1998 to match the S&P 500 index's (SPX) health-care sector. The record for the health-care ETF underscores a rally on Wall Street in late August that has the small-capitalization Russell 2000 index (RUT) the Nasdaq Composite Index (COMP) and the S&P 500 putting records of their own.

  • MarketWatch25 days ago

    Generic EpiPen may not launch in time for allergic kids going back to school

    When Teva Pharmaceutical Industries Ltd.'s (TEVA) generic version of the EpiPen allergic reaction treatment was approved last week, amid spot shortages of the branded product and concerns about allergic children needing the products as they go back to school, the timing seemed perfect. While Labor Day is traditionally thought of as back-to-school season, schools in some parts of the country start as early as July, and elsewhere August is considered the new September, CNN has previously reported.

  • MarketWatch25 days ago

    Mylan stock rises 3% after upgraded to outperform by EvercoreISI

    Mylan NV (MYL) shares rose 2.9% in Friday premarket trade after the company was upgraded to outperform by EvercoreISI analyst Umer Raffat on the strength of its pipeline of copycat biosimilar drugs and new product launches. Excitement about biosimilar drugs has been muted because they haven't sold well, but there's evidence that the competitive factors that have held them up may soon change, he said. Raffat was also hopeful about the company's upcoming product launches, including a branded chronic obstructive pulmonary disease therapy with a Food and Drug Administration approval decision expected in mid-November.

  • InvestorPlace26 days ago

    Why Teva’s Outlook Is Mixed

    Teva Pharmaceutical (NYSE:TEVA) perfectly illustrates the dangers of trading volatile biotech stocks. Last year was particularly horrendous for TEVA stock. The company’s shares lost almost half their market value.

  • Teva Stock Continues to Trend Higher on Positive News
    Market Realist26 days ago

    Teva Stock Continues to Trend Higher on Positive News

    On August 22, Teva Pharmaceutical Industries (TEVA) fell 2.6% as compared to the previous day’s closing price. Over the last week, the company announced FDA (U.S. Food and Drug Administration) approval for its generic version of Mylan’s (MYL) EpiPen on August 16 and the release of positive data released on the same day from Fasinumab, which is being developed in collaboration with Regeneron Pharmaceuticals (REGN) for the treatment of osteoarthritis of the knee or hip. Plus, Berkshire Hathaway announced its portfolio holdings in the second quarter of fiscal 2018 last week, which showed that the company has further increased its stake in Teva Pharmaceutical.

  • Thomson Reuters StreetEvents26 days ago

    Edited Transcript of MYL earnings conference call or presentation 8-Aug-18 2:00pm GMT

    Q2 2018 Mylan NV Earnings Call

  • 3 Stocks That Are Absurdly Cheap Right Now
    Motley Fool27 days ago

    3 Stocks That Are Absurdly Cheap Right Now

    SINA, Mylan, and BB&T Corporation could appeal to value-seeking investors.

  • Reuters28 days ago

    U.S. FDA extends EpiPen expiry date to combat shortage

    The U.S. Food and Drug Administration on Tuesday extended the expiration date of specific lots of Mylan NV's EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment. The shortage has largely been due to ongoing manufacturing issues at a Pfizer plant which supplies EpiPens. EpiPen autoinjectors allow the patient or a caretaker to administer a dose of epinephrine in case of a severe allergic reaction, such as to bee stings or exposure to peanuts.